We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

17 hedge funds and large institutions have $51M invested in Akari Therapeutics in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $49.2M → $51M (+$1.8M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less funds holding

Funds holding: 19 → 17 (-2)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
17
Holders Change
-2
Holders Change %
-10.53%
% of All Funds
0.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
3
Increased
3
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$529K
2
Deutsche Bank
Deutsche Bank
Germany
+$41.5K
3
ACP
Acuta Capital Partners
California
+$20.7K
4
Morgan Stanley
Morgan Stanley
New York
+$20.7K
5
UBS Group
UBS Group
Switzerland
+$10.4K

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$1.77M
2
Millennium Management
Millennium Management
New York
-$743K
3
TI
Turner Investments
Pennsylvania
-$415K
4
EC
EcoR1 Capital
California
-$114K
5
RCM
RA Capital Management
Massachusetts
-$82.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$16.1M – – –
VC
2
Vivo Capital
California
$7.39M +$6.84M +660 New
BBA
3
Baker Bros. Advisors
New York
$5.54M – – –
VMI
4
VHCP Management II
New York
$5.17M – – –
FCMI
5
Foresite Capital Management III
California
$3.69M – – –
QF
6
QVT Financial
New York
$3.21M – – –
RCM
7
RA Capital Management
Massachusetts
$2.6M -$82.9K -8 -2%
VM
8
VHCP Management
New York
$2.22M – – –
BC
9
Boxer Capital
California
$1.96M – – –
EC
10
EcoR1 Capital
California
$1.29M -$114K -11 -9%
GTC
11
Ghost Tree Capital
New York
$653K -$10.4K -1 -2%
SM
12
Sabby Management
Florida
$606K +$529K +51 New
ACP
13
Acuta Capital Partners
California
$236K +$20.7K +2 +10%
Deutsche Bank
14
Deutsche Bank
Germany
$235K +$41.5K +4 +16%
DCM
15
DAFNA Capital Management
California
$66K -$41.5K -4 -40%
UBS Group
16
UBS Group
Switzerland
$18K +$10.4K +1 +100%
Morgan Stanley
17
Morgan Stanley
New York
$18K +$20.7K +2 New
TI
18
Turner Investments
Pennsylvania
$4K -$415K -40 Closed
NMC
19
NEA Management Company
Maryland
– -$1.77M -152 Closed
Millennium Management
20
Millennium Management
New York
– -$743K -64 Closed
Bank of America
21
Bank of America
North Carolina
– -$22K -2 Closed
TRCT
22
Tower Research Capital (TRC)
New York
– -$7K -1 Closed

AKTX Hedge Fund Activity: Q1 2016 in Review

17 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2016, worth a combined $51M — up 3.7% from $49.2M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of AKTX and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $529K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.77M sold.

  • 17 institutional investors held Akari Therapeutics (AKTX) as of Q1 2016, down from 19 in Q4 2015.
  • Funds reported $51M of Akari Therapeutics stock for Q1 2016, up 3.7% quarter-over-quarter.
  • 3 funds opened new Akari Therapeutics positions in Q1 2016 and 5 closed out, a net change of -2 holders.
  • The largest Akari Therapeutics buyer in Q1 2016 was Sabby Management, an estimated $529K added.
  • The largest Akari Therapeutics seller in Q1 2016 was NEA Management Company, an estimated $1.77M sold.

Based on aggregated 13F filings for Q1 2016.